Delving into the Latest Updates on Mometasone furoate/Salicylic acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Combisor, Mometasone/salicylic acid, Monsalic

+ [2]

Target

COX x GR

Mechanism

COX inhibitors(Cyclooxygenases inhibitors), GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Skin and Musculoskeletal Diseases

Active Indication

Skin Diseases

Inactive Indication-

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Merck GmbH

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

PT (04 Aug 2011),

Skin Diseases

Regulation-

Login to view timeline

Structure

Molecular FormulaC27H30Cl2O6

InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N

CAS Registry83919-23-7

View All Structures (2)

The aims is to evaluate the efficacy and comparative isolation of the association Mometasone furoate + Salicylic Acid and the substance isolated Mometasone furoate produced by the Laboratory Glenmark Pharmaceuticals Ltd. in patients of both sexes, patients with plaque psoriasis grade mild to moderate.

Start Date01 Sep 2006

Sponsor / Collaborator

Azidus Brasil

100 Clinical Results associated with Mometasone furoate/Salicylic acid

Login to view more data

100 Translational Medicine associated with Mometasone furoate/Salicylic acid

Login to view more data

100 Patents (Medical) associated with Mometasone furoate/Salicylic acid

Login to view more data

3

Literatures (Medical) associated with Mometasone furoate/Salicylic acid

01 Mar 1998·Steroids

An Unusual Dienone-Phenol Rearrangement Product Formed During the Aynthesis of Mometasone Furoate (Sch 32088) 11Tables of atomic positional and thermal parameters, bond lengths and angles for compound 4 have been deposited at the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK.

Article

Author: Richard W. Draper ; Andrew T. McPhail ; Eugene J. Vater ; Mohindar S. Puar

The structure of an unusual dienone-phenol rearrangement product 4 obtained during the synthesis of mometasone furoate (Sch 32088) was assigned on the basis of NMR and x-ray crystallographic data. The mechanism of formation is discussed.

01 Sep 1995·SteroidsQ4 · MEDICINE

An unusual rearrangement product formed during production of mometasone furoate (Sch 32088)

Q4 · MEDICINE

Article

Author: D. Beiner ; M.S. Puar ; M. Ruggeri ; A.T. McPhail ; P.A. Thompson

The structure of an unusual rearrangement product obtained during the production of mometasone furoate (Sch 32088) was assigned on the basis of NMR and X-ray crystallography data.

01 Jul 1992·Journal of Pharmaceutical and Biomedical AnalysisQ3 · MEDICINE

A competitive enzyme immunoassay for the direct determination of mometasone furoate (SCH 32088) in human plasma

Q3 · MEDICINE

Article

Author: Kevin Byrnes ; Zuguang Tian ; Chang-Jin Wang ; Chin-Chung Lin

Mometasone furoate (SCH 32088) is a synthetic corticosteroid which has a topical anti-inflammatory activity with a minimal potential for suppressing hypothalamic-pituitary-adrenocortical (HPA) axis. A sensitive competitive enzyme immunoassay (EIA) for measuring SCH 32088 in unextracted human plasma has been developed. The 3-(O-carboxymethyl)oxime (CMO) of SCH 32088 was synthesized and conjugated with bovine thyroglobulin, and the product was used for the production of antibodies in rabbits. SCH 32088-3-CMO was also conjugated with horseradish peroxidase, which was used as the tracer. The EIA thus developed can detect 1 pg SCH 32088 per assay or 25 pg per ml of human plasma. It can reliably quantitate SCH 32088 in human plasma from 50 pg ml-1 to 2.5 ng ml-1 with good linearity, accuracy and precision. The assay can be extended to measure SCH 32088 in plasma of laboratory animals. The availability of this sensitive assay makes it possible to evaluate the pharmacokinetics and toxicokinetics of SCH 32088 in laboratory animals and man.

100 Deals associated with Mometasone furoate/Salicylic acid

Login to view more data